Abstract 778
Case Summary
This case report is a 64-year-old male presented with progressive right hemiparesis 2 months. CT brain shown left frontal mass with perilesional edema size 15*11 cm. He underwent to craniotomy and tumor removal. Histopathology of brain and dura tissues reported anaplastic meningioma (WHO grade III) with mitotic activity 20/10 HPF. In October 2016, he presented with masses at the scalp and 4 months later he had right hemiparesis and right facial palsy. MRI brain shown progressive left frontal lobe meningioma multiple scalp mass. In February 2017, the patient underwent for left frontal craniotomy with tumor removal. Pathological reported anaplastic (WHO grade III) with mitotic activity 20/10 HPF. CT chest shown multiple pulmonary nodules both lungs, enlarge hypodense node at a periaortic area and new develop right hypovascular nodule at the right kidney. Then he undergone the bronchoscopy but histopathologic had reported the presence of lung tissue with mild inflammation. That time he had received tamoxifen 20 mg once daily. Then he did Intensity-modulated radiotherapy (IMRT) at brain and scalp lesion. A tamoxifen was started in February 2017 until May 2017. Followed Magnetic resonance imaging (MRI) shown progressive of the residual at left frontotemporal regions with left frontal lobe invasion. CT chest was reported increased pleural effusion at right lung and increased both multiple solids nodules and mediastinal nodes. In June 2017, Pleural effusion had rapid increase in volume. After there he had been done pleuroscopy for pleural biopsy and talc pleurodesis. Histopathological of pleura shown metastatic meningioma. Immunohistochemistry shown positive EMA and D2-40 and negative for AE1/AE3, TTF-1, P40, calretinin, WT1, and CAM5.2. Then the patient had been palliative care until passed
Anaplastic meningioma is uncommon and poor prognosis tumor. It found about 2-3 % of all meningiomas. The tumor is aggressive and rapid growing and a higher rate of recurrence. The treatment of choice is complete surgery followed by radiotherapy. There is no standard effective of chemotherapy. Some evidence suggests hormonal therapy which use tamoxifen to treat inoperable meningioma. In this patient was received tamoxifen but poor response rate and finally tumor has a progression
Editorial acknowledgement
Clinical trial identification
Resources from the same session
905 - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy
Presenter: Umesh Velu
Session: Poster display - Cocktail
Resources:
Abstract
1060 - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?
Presenter: Kartika Taroeno-Hariadi
Session: Poster display - Cocktail
Resources:
Abstract
1148 - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali
Presenter: Anak Agung Lestari
Session: Poster display - Cocktail
Resources:
Abstract
400 - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Norikazu Masuda
Session: Poster display - Cocktail
Resources:
Abstract
801 - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer
Presenter: Mohamed Elbaiomy
Session: Poster display - Cocktail
Resources:
Abstract
1014 - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®
Presenter: Quanying Zhang
Session: Poster display - Cocktail
Resources:
Abstract
1138 - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s
Presenter: Yunjie He
Session: Poster display - Cocktail
Resources:
Abstract
145 - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.
Presenter: Abhishek Anand
Session: Poster display - Cocktail
Resources:
Abstract
804 - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer
Presenter: John Robertson
Session: Poster display - Cocktail
Resources:
Abstract
1154 - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients
Presenter: Sung Soo Kang
Session: Poster display - Cocktail
Resources:
Abstract